A phase 1 study of ARX788, a HER2-targeting antibody-drug conjugate, in patients with metastatic HER2-positive breast cancer

首页> 外文期刊>Intelligence: A Multidisciplinary Journal >A phase 1 study of ARX788, a HER2-targeting antibody-drug conjugate, in patients with metastatic HER2-positive breast cancer

【24h】

A phase 1 study of ARX788, a HER2-targeting antibody-drug conjugate, in patients with metastatic HER2-positive breast cancer

机译：ARX788，ARX788，一种靶向抗体 - 药物缀合物，转移HER2阳性乳腺癌患者的阶段1研究

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Intelligence: A Multidisciplinary Journal》 |2020年第2020期|共2页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心理学;
关键词

相似文献

外文文献
中文文献
专利

1. A phase 1 study of ARX788, a HER2-targeting antibody-drug conjugate, in patients with metastatic HER2-positive breast cancer [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：ARX788，ARX788，一种靶向抗体 - 药物缀合物，转移HER2阳性乳腺癌患者的阶段1研究
2. Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer [J] . BendellJ., SalehM., RoseA.A.N., Journal of Clinical Oncology . 2014,第32期

机译：抗体-药物偶联物格伦巴单抗vedotin在局部晚期或转移性乳腺癌患者中的I / II期研究
3. Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer [J] . BendellJ., SalehM., RoseA.A.N., Journal of Clinical Oncology . 2014,第32期

机译：抗体-药物偶联物格伦巴单抗vedotin在局部晚期或转移性乳腺癌患者中的I / II期研究
4. Effects of laser immunotherapy on late-stage, metastatic breast cancer patients in a Phase Ⅱ clinical trial [C] . Gabriela L. Ferrel, Feifan Zhou, Xiaosong Li, Biophotonics and immune responses IX . 2014

机译：Ⅱ期临床试验中激光免疫疗法对晚期转移性乳腺癌患者的影响
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Safety and pharmacokinetics of MM-302 a HER2-targeted antibody–liposomal doxorubicin conjugate in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study [O] . Pamela Munster, Ian E. Krop, Patricia LoRusso, 2018

机译：MM-302（一种靶向HER2的抗体-脂质体阿霉素结合物）在晚期HER2阳性乳腺癌患者中的安全性和药代动力学：一项1期剂量递增研究
7. DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance [O] . Naoki Takegawa, Yoshikane Nonagase, Kimio Yonesaka, 2017

机译：DS-8201A，一种掺入新型DNA拓扑异构酶I抑制剂的新的HER2靶向抗体 - 药物缀合物，克服了HER2阳性胃癌T-DM1抗性

A phase 1 study of ARX788, a HER2-targeting antibody-drug conjugate, in patients with metastatic HER2-positive breast cancer

著录项

引文网络

相似文献

相关主题

期刊订阅